Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway

Hao,Yanmei; Zhang,Nan; Wei,Nannan; Yin,Hongmei; Zhang,Yingjie; Xu,Hui; Zhu,Chaomang; Li,Duojie

doi:10.3892/ol.2019.10649

Matrine induces apoptosis in acute myeloid leukemia cells by inhibiting the PI3K/Akt/mTOR signaling pathway

Authors:
- Yanmei Hao
- Nan Zhang
- Nannan Wei
- Hongmei Yin
- Yingjie Zhang
- Hui Xu
- Chaomang Zhu
- Duojie Li
View Affiliations

Affiliations: Department of Clinical Laboratory, Bengbu Medical College, Bengbu, Anhui 233004, P.R. China, Department of Radiotherapy, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P.R. China
Published online on: July 22, 2019 https://doi.org/10.3892/ol.2019.10649
Pages: 2891-2896
Copyright: © Hao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrine has been demonstrated to exert anticancer effects on acute myeloid leukemia (AML) cell lines. However, the mechanisms of matrine in AML remain largely unknown. The present study investigated the anticancer effects and underlying mechanisms of matrine on human AML cells in vitro. THP‑1 cell lines were cultured and treated with different doses of matrine (0.4, 0.8, 1.2, 1.6 and 2.0 g/l). The effects of matrine on the cell proliferation were assessed by the Cell Counting Kit‑8 assay. The apoptotic effects were evaluated by DAPI and annexin V/propidium iodide staining assays. The effects of the drug on phosphoinositide 3‑kinase (PI3K)/protein kinase B (Akt)/ mechanistic target of rapamycin kinase (mTOR) protein expression were studied by western blot analysis. The results of the present study demonstrated that matrine suppressed the viability of THP‑1 cells. The anticancer effects were identified to be dose‑dependent and the IC50 value was 1.2 g/l in THP‑1 cells. Matrine inhibited cell viability and induced cell apoptosis of AML cell lines in a dose‑ and time‑dependent manner. In addition, it was observed that matrine decreased the expression of phosphorylated (p)‑PI3K, p‑Akt and p‑mTOR in a concentration‑dependent manner. However, the expression levels of PI3K, Akt and mTOR remained almost unaltered. These findings indicated that matrine may inhibit cell proliferation and induce apoptosis of AML cells and may be a novel effective chemotherapeutic agent against AML.

View Figures

View References

1	Döhner H, Weisdorf DJ and Bloomfield CD: Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015. View Article : Google Scholar : PubMed/NCBI
2	Estey EH: Therapeutic options for acute myelogenous leukemia. Cancer. 92:1059–1073. 2001. View Article : Google Scholar : PubMed/NCBI
3	Jabo B, Morgan JW, Martinez ME, Ghamsary M and Wieduwilt MJ: Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. PLoS One. 12:e01747602017. View Article : Google Scholar : PubMed/NCBI
4	Kwong YL, Au WY, Chim CS, Pang A, Suen C and Liang R: Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukemia: Clinicopathological and molecular features of a pilot study. Am J Hematol. 66:274–279. 2001. View Article : Google Scholar : PubMed/NCBI
5	George B, Mathews V, Vishwabandhya A, Srivastava A and Chandy ML: Arsenic Trioxide (As2O3) in the treatment of patients with newly diagnosed acute promyelocytic leukemia (APML)-Toxicity and outcome. Blood. 104:8892004.PubMed/NCBI
6	Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S and Cortes J: Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: The M. D. Anderson experience. Cancer. 97:2218–2224. 2003. View Article : Google Scholar : PubMed/NCBI
7	Zhou H, Xu M, Gao Y, Deng Z, Cao H, Zhang W, Wang Q, Zhang B, Song G, Zhan Y and Hu T: Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factor. Mol Cancer. 13:592014. View Article : Google Scholar : PubMed/NCBI
8	Zhang Y, Zhang H, Yu P, Liu Q, Liu K, Duan H, Luan G, Yagasaki K and Zhang G: Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology. 59:191–200. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang S, Zhang Y, Zhuang Y, Wang J, Ye J, Zhang S, Wu J, Yu K and Han Y: Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation. PLoS One. 7:e468532012. View Article : Google Scholar : PubMed/NCBI
10	Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, Liu BZ and He YJ: Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res. 25:793–800. 2001. View Article : Google Scholar : PubMed/NCBI
11	Yong-Qing Z, Gao-Sheng H and Hong-Jun L: Cells differential orientation in K562 cell line with matrine induction. J Oncol. 10:25–27. 2004.
12	Xu Q, Simpson SE, Scialla TJ, Bagg A and Carroll M: Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
13	Kubota Y, Ohnishi H, Kitanaka A, Ishida T and Tanaka T: Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: Direct evidence of PI3K activation. Leukemia. 18:1438–1440. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dores GM, Devesa SS, Curtis RE, Linet MS and Morton LM: Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood. 119:342012. View Article : Google Scholar : PubMed/NCBI
15	Krug U, Röllig C, Koschmieder A, Heinecke A, Sauerland MC, Schaich M, Thiede C, Kramer M, Braess J, Spiekermann K, et al: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet. 376:2000–2008. 2010. View Article : Google Scholar : PubMed/NCBI
16	Gao HY, Li GY, Lou MM, Li XY, Wei XY and Wang JH: Hepatoprotective effect of Matrine salvianolic acid B salt on carbon tetrachloride-induced hepatic fibrosis. J Inflamm (Lond). 9:162012. View Article : Google Scholar : PubMed/NCBI
17	Chen JX, Shen HH, Niu M, Guo YM, Liu XQ, Han YZ, Zhang YM, Zhao YL, Bai BK, Zhou WJ and Xiao XH: Anti-hepatitis B virus effect of matrine-type alkaloid and involvement of p38 mitogen-activated protein kinase and tumor necrosis factor receptor-associated factor 6. Virus Res. 215:104–113. 2016. View Article : Google Scholar : PubMed/NCBI
18	Ma L, Zhu Z, Jiang L, Sun X, Lu X, Zhou M, Qian S and Li J: Matrine suppresses cell growth of human chronic myeloid leukemia cells via its inhibition of the interleukin-6/Janus activated kinase/signal transducer and activator of transcription 3 signaling cohort. Leuk Lymphoma. 56:2923–2930. 2015. View Article : Google Scholar : PubMed/NCBI
19	Yang Y, Guo JX, Shao ZQ and Gao JP: Matrine inhibits bladder cancer cell growth and invasion in vitro through PI3K/AKT signaling pathway: An experimental study. Asian Pac J Trop Med. 10:515–519. 2017. View Article : Google Scholar : PubMed/NCBI
20	Ishikawa Y: Genetic abnormalities in core binding factor acute myeloid leukemia. Rinsho Ketsuek (Japanese). 58:991–998. 2017.
21	Illendula A, Pulikkan JA, Zong H, Grembecka J, Xue L, Sen S, Zhou Y, Boulton A, Kuntimaddi A, Gao Y, et al: Chemical biology. A small-molecule inhibitor of the aberrant transcription factor CBFβ-SMMHC delays leukemia in mice. Science. 347:779–784. 2015. View Article : Google Scholar : PubMed/NCBI
22	Morgensztern D and Mcleod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 16:797–803. 2005. View Article : Google Scholar : PubMed/NCBI
23	Jin R, Jin YY, Tang YL, Yang HJ, Zhou XQ and Lei Z: GPNMB silencing suppresses the proliferation and metastasis of osteosarcoma cells by blocking the PI3K/Akt/mTOR signaling pathway. Oncol Rep. 39:3034–3040. 2018.PubMed/NCBI
24	Qi L, Sun K, Zhuang Y, Yang J and Chen J: Study on the association between PI3K/AKT/mTOR signaling pathway gene polymorphism and susceptibility to gastric cancer. J BUON. 22:1488–1493. 2017.PubMed/NCBI
25	Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, et al: Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood. 110:1025–1028. 2007. View Article : Google Scholar : PubMed/NCBI
26	Park S, Chapuis N, Tamburini J, Bardet V, Cornilletlefebvre P, Willems L, Green A, Mayeux P, Lacombe C and Bouscary D: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 95:819–828. 2010. View Article : Google Scholar : PubMed/NCBI
27	Wu J, Hu G, Dong Y, Ma R, Yu Z, Jiang S, Han Y, Yu K and Zhang S: Matrine induces Akt/mTOR signalling inhibition-mediated autophagy and apoptosis in acute myeloid leukaemia cells. J Cell Mol Med. 21:1171–1181. 2017. View Article : Google Scholar : PubMed/NCBI